Overview: Propoxyphene Screen TestIntroduction: The Propoxyphene Screen Test screens for propoxyphene to diagnose drug abuse, causing sedation or confusion. Following 2023 SAMHSA guidelines, it uses biochemical methods for high specificity, supporting toxicology screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in toxicology for patients with suspected propoxyphene exposure.
Other Names: Propoxyphene Screen Assay, Darvon Screen Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Propoxyphene screening began in the 1970s with opioid abuse research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Screens for propoxyphene to diagnose drug abuse, guides treatment, and evaluates patients with sedation or confusion.
Test Parameters: 1. Propoxyphene Presence
Pretest Condition: No fasting required. Collect urine, serum, plasma, or hair. Report history of sedation, confusion, or drug exposure.
Specimen: Urine (sterile container, 5-20 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Hair (sterile container, 1-2 gm). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document sedation, confusion, or history of drug abuse. Include current medications, especially opioids.
Consent: Written consent required, detailing the tests purpose, drug abuse implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to screen for propoxyphene presence. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for drug abuse screening.
Factors Affecting Result Accuracy: Improper sample collection or contamination can affect results. Cross-reactivity with other opioids may reduce specificity.
Clinical Significance: Positive propoxyphene screen suggests drug abuse, guiding confirmatory testing or rehabilitation. Negative results may require GC-MS confirmation.
Specialist Consultation: Consult a toxicologist or addiction specialist for result interpretation and treatment planning.
Additional Supporting Tests: Propoxyphene confirmation test, urine drug panel, or clinical evaluation to confirm drug abuse.
Test Limitations: False positives may occur; clinical correlation is needed. Sample quality affects sensitivity.
References: SAMHSA Drug Testing Guidelines, 2023; Journal of Analytical Toxicology, Baselt RC, 2022.
